Table 2.
Direct and indirect effects of SARS-CoV-2 pandemic in the study population.
| FH (n = 260) before Lockdown | FH (n = 260) after Lockdown | p Value | |
|---|---|---|---|
| Indirect Effect | |||
| Lipid Profile, n (%) | 260 (100.0) | 147 (56.5) | <0.01 |
| TC, mg/dL * | 169.61 ± 18.75 | 177.83 ± 18.91 | 0.43 |
| HDL-C, mg/dL * | 53.2 ± 10.38 | 47.78 ± 10.12 | <0.05 |
| TG, mg/dL * | 90.5 (68.25–114.5) | 97.5 (70.5–121.25) | 0.11 |
| LDL-C, mg/dL * | 103.13 ± 18.02 | 111.32 ± 18.14 | 0.25 |
| Non-HDL-C, mg/dL * | 117.24 ± 18.83 | 133.09 ± 19.01 | <0.05 |
| LDL-C target, n (%) * | 105 (40.4) | 81 (31.2) | 0.09 |
| Lipidologist consultation, n (%) | 260 (100.0) | 87 (33.5) | <0.001 |
| Cardiologist consultation, n (%) | 158 (60.8) | 58 (22.3) | <0.01 |
| Vascular imaging, n (%) | 260 (100.0) | 51 (19.6) | <0.001 |
| Cause of Indirect Effect | |||
| Contagion fear, n (%) | - | 218 (83.8) | - |
| Long-wait consultation, n (%) | - | 42 (16.2) | - |
| Direct Effect | |||
| SARS-CoV-2 infection, n (%) | - | 19 (7.3) | - |
| Hospitalization | |||
| COVID-19, n (%) | - | - | - |
| Other causes, n (%) | - | - | - |
Data are presented as mean ± standard deviation, percentages, or median (interquartile range). FH = familial hypercholesterolemia, TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol, LLT = lipid-lowering therapy, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, COVID = coronavirus disease. * Student’s t-test was performed in subjects for whom the lipid profile was evaluated before and after lockdown.